文献速递常见症状与未分化疾病预防保健、筛查与疫苗

FluScoreVax流感风险评分:结合疫苗接种史的开发与外部验证

Development and External Validation of the FluScoreVax Risk Score for Influenza That Incorporates Vaccine Status.
PubMed 文献 · J Am Board Fam Med · 2025-09-15

基于欧洲GRACE数据开发并内部验证、美国EAST-PC数据外部验证的流感诊断风险评分,纳入主观发热、活动受限、头痛、喘息、咳痰和近期流感疫苗接种6项,评分范围-5至6分,外部验证AUC为0.75,低风险组占61%且流感患病率仅6.8%。

要点

  • FluScoreVax评分含6项指标,总分范围-5至6分,已开发为应用程序。
  • 外部验证AUC为0.75,低、中、高风险组流感患病率分别为6.8%、21.8%、35.3%。
  • 低风险组占外部验证人群61%,其中仅约7%确诊流感。

核心结论

  • FluScoreVax风险评分可在外部队列中良好区分流感风险,低风险组占61%且流感患病率仅7%。

研究设计与样本

  • 使用2007至2010年12个欧洲国家因急性咳嗽就诊的成人门诊患者数据(GRACE)开发并内部验证评分,采用逻辑回归基于β系数赋分。
  • 使用同期美国数据(EAST-PC)进行外部验证,以PCR确诊流感,通过各风险组流感患病率和AUC评估准确性,并绘制观察值与预期值评估校准。

主要发现

  • 开发出含6项(主观发热、活动受限、头痛、喘息、咳痰、近期流感疫苗)的风险评分,范围-5至6分。
  • 开发和内部验证子组的AUC均为0.75。
  • GRACE数据流感患病率为15.1%,EAST-PC数据为14.4%。
  • 外部验证中低、中、高风险组流感患病率分别为6.8%、21.8%、35.3%,低风险组占61%。
  • 校准优秀。

关键数值与推荐

  • 评分包含主观发热、活动受限、头痛、喘息、咳痰和近期流感疫苗接种6项,总分范围-5至6分。
  • 外部验证AUC为0.75,低风险组流感患病率6.8%,中风险组21.8%,高风险组35.3%。

临床怎么用

  • 可用于流感季成人急性咳嗽门诊患者的风险分层,低风险组(占61%)流感可能性低(约7%),或可辅助减少不必要的检测或抗病毒治疗。
  • 评分已开发为应用程序,便于临床快速计算。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: To develop and externally validate a simple risk score for influenza diagnosis based using vaccination history and patient-reported symptoms. METHODS: Adult outpatients in 12 European countries during flu season with a chief complaint of acute cough between 2007 and 2010 were used to derive and internally validate the risk score (Genomics to combat Resistance against Antibiotics in Community acquired LRTI in Europe (GRACE) data), and contemporary US data were used for external validation (EAST-PC data). Patient-reported symptoms were recorded and polymerase chain reaction (PCR) was used to diagnose influenza. The score was derived using logistic regression and assigning points based on the β -coefficients. The score was externally validated in a contemporary US population (EAST-PC data). Accuracy was measured using influenza prevalence in each risk group and the area under the receiver operating characteristic curve (AUC). Calibration was assessed by plotting observed versus expected. RESULTS: We developed a risk score with 6 items (subjective fever, interfered with usual activity, headache, wheeze, phlegm, and recent flu vaccine) and a range from -5 to 6 points. The AUC was 0.75 for both derivation and internal validation subgroups. The prevalence of influenza was 15.1% in the GRACE data and 14.4% in the EAST-PC data. The percentage with influenza in the low, moderate, and high-risk groups was 6.8%, 21.8%, 35.3 in the external validation population (EAST-PC data). The low-risk group included 61% of participants in the external validation. Calibration was excellent. CONCLUSIONS: We developed and externally validated the FluScoreVax risk score, available as an app. It classifies 61% of patients as low risk, of whom only 7% had influenza.

来源:J Am Board Fam Med,查看原文。版权归原作者所有。

引用

  1. Ebell MH, Chen Y, Luo F, et al. Development and External Validation of the FluScoreVax Risk Score for Influenza That Incorporates Vaccine Status. J Am Board Fam Med. 2025. PMID: 40789620. doi:10.3122/jabfm.2024.240366R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。